Clinical Perspectives
In patients with severe MR, RV dysfunction is associated with increased
adverse outcomes. TAPSE was an independent predictor of CV events
following MitraClip therapy. Its cut-off value (11%) may be
independently available to predict CV events following MitraClip
therapy. The present study comprised a small sample size and focused on
short-term results. Properly designed trials with longer follow-up and
more patients are required to confirm our results.